Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection

被引：26

作者：

Rabaud, C ^{[1
]}

Burty, C

Grandidier, M

Christian, B

Penalba, C

Béguinot, I

Jeanmaire, H

May, T

机构：

[1] Ctr Informat & Soins Immunodeficience Humaine, Lorraine Champagne Arden, France

[2] CHU Nancy, Hop Brabois, Serv Malad Infect & Trop, F-54511 Vandoeuvre Les Nancy, France

来源：

CLINICAL INFECTIOUS DISEASES | 2005年 / 40卷 / 02期

关键词：

D O I：

10.1086/426589

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Tolerability of the combination of zidovudine-lamivudine and lopinavir-ritonavir as postexposure prophylaxis (PEP) for human immunodeficiency virus infection was prospectively assessed. A total of 121 patients were enrolled in the study; 23 patients discontinued PEP prematurely for reasons other than adverse events. Of the other 98 patients, 58 (59%) experienced adverse effects, which led to premature PEP discontinuation in 20 cases (20%).

引用

页码：303 / 305

页数：3

共 12 条

[1]

de la Tribonniere X, 1998, INT J STD AIDS, V9, P591, DOI 10.1258/0956462981921170

[2] Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases [J].

Doco-Lecompte, T ;

Garrec, A ;

Thomas, L ;

Trechot, P ;

May, T ;

Rabaud, C .

AIDS, 2004, 18 (04) :705-706

[3]

Ippolito Giuseppe, 1997, American Journal of Medicine, V102, P58, DOI 10.1016/S0002-9343(97)00064-8

[4] Post-exposure prophylaxis after non-occupational HIV exposure: impact of recommendations on physicians' experiences and attitudes [J].

Laporte, A ;

Jourdan, N ;

Bouvet, E ;

Lamontagne, F ;

Pillonel, J ;

Desenclos, JC .

AIDS, 2002, 16 (03) :397-405

[5] Tolerability of postexposure antiretroviral prophylaxis for occupational exposures to HIV [J].

Lee, LM ;

Henderson, DK .

DRUG SAFETY, 2001, 24 (08) :587-597

[6] Tolerability and side-effects of post-exposure prophylaxis for HIV infection [J].

Parkin, JM ;

Murphy, M ;

Anderson, J ;

El-Gadi, S ;

Forster, G ;

Pinching, AJ .

LANCET, 2000, 355 (9205) :722-723

[7]

Puro V, 2001, J BIOL REG HOMEOS AG, V15, P238

[8] Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection [J].

Rabaud, C ;

Bevilacqua, S ;

Beguinot, I ;

Dorvaux, V ;

Schuhmacher, H ;

May, T ;

Canton, P .

CLINICAL INFECTIOUS DISEASES, 2001, 32 (10) :1494-1495

[9] Experience of healthcare workers taking postexposure prophylaxis after occupational HIV exposures: Findings of the HIV postexposure prophylaxis registry [J].

Wang, SA ;

Panlilio, AL ;

Doi, PA ;

White, AD ;

Stek, M ;

Saah, A .

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2000, 21 (12) :780-785

[10] Transmission of antiretroviral-drug-resistant HIV-1 variants [J].

Yerly, S ;

Kaiser, L ;

Race, E ;

Bru, JP ;

Clavel, F ;

Perrin, L .

LANCET, 1999, 354 (9180) :729-733

← 1 2 →